Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × brexucabtagene autoleucel × 1 year × Clear all

Phase

Phase 2 8 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, B-Cell 1

Interventions

pembrolizumab 191 Nivolumab 108 Cyclophosphamide 105 Carboplatin 88 venetoclax 69 Gemcitabine 67 Bevacizumab 67 fludarabine 63 Dexamethasone 62 Specimen Handling 60 Injections 59 Magnetic Resonance Spectroscopy 57 Paclitaxel 56 Biopsy 54 atezolizumab 53 Cisplatin 47 Ipilimumab 46 Temozolomide 42 Rituximab 42 Pemetrexed 41 Docetaxel 39 Azacitidine 39 Oxaliplatin 38 Radiotherapy 37 Lenalidomide 35 Fluorouracil 35 Cetuximab 35 Prednisone 34 Irinotecan 33 Cytarabine 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02625480 2025-09-29

ZUMA-4

Gilead Sciences

Phase 1/2 Active not recruiting

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡